Grant Funded Startups in France
The largest disclosed grant among the 12 most recent entries is Osivax’ $11M grant dated 2022-06-23, which dwarfs the rest of the disclosed amounts in this…
The largest disclosed grant among the 12 most recent entries is Osivax’ $11M grant dated 2022-06-23, which dwarfs the rest of the disclosed amounts in this view; most other disclosed grants sit in the tens or low single-digit millions (e.g., Signia Therapeutics and Pherecydes Pharma at $2M on 2022-01-04 and 2022-01-03, and several $500K-or-below grants such as Qonto’s $500K on 2022-10-20 and Codman Square Health Center’s $50K on 2022-05-03). Biotech is the clearest sector cluster, appearing in 4 of the 12 companies (Osivax, Pherecydes Pharma, EVerZom, MaaT Pharma), while multiple grants also concentrate in the Ile-de-France geography (Qonto in Paris on 2022-10-20; Enalees in Évry on 2022-10-24; Tilkal in Paris on 2022-10-14; Pherecydes Pharma in Romainville on 2022-01-03; and EVerZom in Paris on 2021-11-18). Temporally, the latest round shown is Enalees’ $490K grant on 2022-10-24, and the oldest is MaaT Pharma’s $2M grant on 2021-07-20, with a notable tightening into mid-2022 around Osivax’ $11M (2022-06-23) and EcoTree’s $510K (2022-07-06).
Most recent rounds
12 shownRelated listings
Frequently asked
What stands out in grant size, and how does the largest disclosed round compare to the rest?
Osivax’ $11M grant (2022-06-23) is the only disclosed amount in the $10M+ range, while the next-largest disclosed grants are $3M for EVerZom (2021-11-18) and $2M for multiple biotech entries such as Signia Therapeutics (2022-01-04) and Pherecydes Pharma (2022-01-03).
Are there tight temporal clusters in the most recent grant dates?
Yes: three grants in this view close in late October 2022—Enalees ($490K, 2022-10-24), Qonto ($500K, 2022-10-20), and Tilkal (undisclosed, 2022-10-14). A second concentration appears in early-to-mid 2022 around Osivax ($11M, 2022-06-23), EcoTree ($510K, 2022-07-06), and Signia Therapeutics ($2M, 2022-01-04) / Pherecydes Pharma ($2M, 2022-01-03).
Which sectors appear most often, and what does that imply for where buyers/suppliers should focus?
Biotechnology is overrepresented relative to other categories here: it appears in 4 of 12 companies (Osivax; Pherecydes Pharma; EVerZom; MaaT Pharma) with disclosed amounts ranging from $2M to $11M (e.g., Osivax at $11M on 2022-06-23). Health Care also repeats, with Enalees, University of Maryland Capital Region Health, Codman Square Health Center, and Signia Therapeutics (4 of 12).
Does any single geography dominate the list, or are rounds spread across France?
Ile-de-France shows up repeatedly (Paris/Évry/Romainville): Qonto (Paris, $500K on 2022-10-20), Enalees (Évry, $490K on 2022-10-24), Tilkal (Paris, undisclosed on 2022-10-14), Pherecydes Pharma (Romainville, $2M on 2022-01-03), and EVerZom (Paris, $3M on 2021-11-18). Other cities are present but less frequent, such as Lyon (Osivax and EVerZom regionally; plus MaaT Pharma in Lyon) and Nantes (HelioRec, $60K on 2022-08-08).
Are there outliers besides the largest grant amount, including the smallest disclosed round and disclosure gaps?
The smallest disclosed amount is HelioRec’s $60K grant (2022-08-08), which is far below the high end (Osivax $11M on 2022-06-23). There is also a disclosure outlier in the low end where Tilkal’s 2022-10-14 grant is undisclosed, creating a gap in what can be compared around the late-October cluster.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.